A Phase 4 interventional study of ALA in Actinic Keratoses, sponsored by Shanghai Dermatology Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-19.
Sponsored by Shanghai Dermatology Hospital · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Aminolevulinic Acid in Keratosis, Actinic — 1 open to participants now, 2 under way, none of them phase 3. Aminolevulinic Acid · Keratosis, Actinic.
Among the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2018, is one of 8 in phase 4, and was the 24th registered.
343 studies on the registry are indexed under Keratosis, Actinic; 30 are open to participants now.
Browse Keratosis, Actinic studies →1 of the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic is open now, in 1 country.
By country, each count listing its studies:
Aminolevulinic Acid: first FDA approval 1999 (LEVULAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 22 Keratosis, Actinic studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 5 · Phase 4 8
First in 1997; this study’s year is marked. 2 started in 2018.
This study's planned enrollment of 300 is above the median of 60 across 295 interventional studies indexed under Keratosis, Actinic.
Median enrollment 32 across the 29 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 29 have an industry lead sponsor. The 10 most frequent:
Shanghai Dermatology Hospital is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Shanghai Dermatology Hospital has 3 studies filed under Keratosis, Actinic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background Actinic keratoses (AKs) are often treated separately, lesion by lesion. However, in the past years, AKs have been described as a field disease and not limited to single clinically apparent lesions. Treatment should therefore target an area of field change which may treat the subclinical AKs and reduce the risk of development of further AKs, second tumours, and local recurrence.
Objectives The investigators sought to investigate whether field ALA-PDT of facial actinic keratosis would prevent new AKs, in comparison with a lesion area receiving the same ALA-PDT, in patients with clinical signs of field cancerization.
Methods Eighty patients, previously diagnosed as having AKs of the face, were randomized distribution into two groups. 10% aminolaevulinic acid (ALA)-PDT for field treatment was on one group and for a lesion area (Vehicle control cream was applied to the non-lesion area) was on the other group. During the next 5-year period of follow up, patients were clinically evaluated for new AKs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Immediately afterwards, a 1-mm thick layer of 10% ALA was applied to the all face. The area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
Drug: ALA
Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Then a 1-mm thick layer of 10% ALA was applied to the lesion and 5 mm of surrounding healthy tissue. Vehicle control cream was applied to the non-lesion area. All area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
Drug: ALA
In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.
Also known as: Aminolevulinic Acid
Number of new Actinic Keratoses
The change in number of actinic keratoses at each follow-up will be measured as the primary outcome
Time frame: 1, 3, 6, 9, 12, 18, 24, 30, 36 months after treatment
The clearance rate of Actinic Keratoses
The change rate in lesion clearance of Actinic Keratoses at one month after treatment will be measured as the second outcome
Time frame: 1 month after treatment
Plan to share: Yes — underlie results
Supporting information: Clinical study report
Time frame: One year after finishing this study and for permanency
Access criteria: anyone who search pubmed
Data sharing details ↗ · www.ncbi.nlm.nih.gov
Started Aug 2018 (actual). Primary completion is estimated for Jun 2025, 81 months after the start.
Of 19 phase 4 interventional studies under Keratosis, Actinic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's planned 81 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aminolevulinic Acid
Shanghai Dermatology Hospital